文献速递糖尿病

自适应与创新试验设计在糖尿病研究中的应用:范围综述

The Role of Adaptive and Innovative Trial Designs in Diabetes Research: A Scoping Review.
PubMed 文献 · Diabetes Care · 2026-01-01

本范围综述系统检索多个数据库与临床试验注册库,旨在映射自适应与主方案设计在1型和2型糖尿病干预性试验中的使用情况。筛查396篇文章后,仅6项已发表自适应试验符合纳入标准(3项1型糖尿病、1项2型糖尿病、2项糖尿病相关神经病变),未发现已发表的平台、篮式或伞式试验;注册库检索发现6项正在进行的1型糖尿病自适应试验,其中4项在自适应平台主方案下。结论认为此类试验在糖尿病领域仍罕见,需通过培训、监管框架和激励措施促进更广泛应用。

要点

  • 糖尿病领域自适应与主方案试验仍罕见,已发表仅6项自适应试验。
  • 已发表试验多用于剂量探索、反应自适应随机化和样本量重估计。
  • 未发现已发表的平台、篮式或伞式试验。

核心结论

  • 自适应与主方案试验在糖尿病研究中仍属罕见,需通过针对性培训、监管框架和战略激励促进更广泛采用。

研究设计与样本

  • 范围综述,系统检索MEDLINE、Embase、CENTRAL、Emcare、Global Health、Web of Science及临床试验注册库,并补充灰色文献检索。
  • 筛查396篇文章,纳入使用自适应、平台、篮式或伞式设计的1型或2型糖尿病干预性试验。

主要发现

  • 6项已发表自适应试验符合纳入标准:3项在1型糖尿病、1项在2型糖尿病、2项在糖尿病相关神经病变。
  • 多数试验将自适应特征用于剂量探索、反应自适应随机化和样本量重估计。
  • 未识别到已发表的平台、篮式或伞式试验。
  • 注册库检索发现6项正在进行的1型糖尿病自适应试验,其中4项在自适应平台主方案下。

临床怎么用

  • 内分泌科医生可关注自适应设计在剂量探索和样本量重估计中的应用价值,并留意正在进行的1型糖尿病自适应平台试验。

局限性

  • 尽管检索全面,仍可能遗漏部分灰色文献和未发表研究。
  • 未进行偏倚风险评估,符合范围综述方法学。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Adaptive and master protocol clinical trials offer significant advantages for diabetes research, including enhanced efficiency and personalized treatment strategies. PURPOSE: This scoping review aimed to systematically map the use of adaptive and master protocol designs in interventional trials for type 1 and type 2 diabetes, identify research gaps, and highlight opportunities for broader implementation. DATA SOURCES: A systematic literature search was performed using MEDLINE, Embase, CENTRAL, Emcare, Global Health, Web of Science, and clinical trial registries. Gray literature searches complemented database findings. STUDY SELECTION: Studies using adaptive, platform, basket, or umbrella trial designs in people with type 1 or type 2 diabetes were included. DATA EXTRACTION: Data were charted using a standardized form. Extracted variables included diabetes type, trial design, adaptive features, interventions, end points, and key findings. DATA SYNTHESIS: Of 396 articles screened, 6 published adaptive trials met the inclusion criteria: 3 in type 1 diabetes, 1 in type 2 diabetes, and 2 in diabetes-related neuropathy. Most used adaptive features for dose finding, response-adaptive randomization, and sample size reestimation. No published platform, basket, or umbrella trials were identified. Six ongoing adaptive trials in type 1 diabetes were identified through registry searches, four under an adaptive platform master protocol. LIMITATIONS: Despite a comprehensive search, some gray literature and unpublished studies may have been missed. Risk of bias was not assessed, consistent with scoping review methodology. CONCLUSIONS: Adaptive and master protocol trials remain rare in diabetes. Overcoming barriers through targeted training and awareness, robust regulatory frameworks, and strategic incentives could support broader adoption.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Goshrani A, Lin R, Churilov L, et al. The Role of Adaptive and Innovative Trial Designs in Diabetes Research: A Scoping Review. Diabetes Care. 2026. PMID: 41264554. doi:10.2337/dc25-1508

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。